Litigation Details for THERAPEUTICSMD, INC. v. AMNEAL PHARMACEUTICALS, INC. (D.N.J. 2020)

✉ Email this page to a colleague

THERAPEUTICSMD, INC. v. AMNEAL PHARMACEUTICALS, INC. (D.N.J. 2020)

Docket	⤷ Start Trial	Date Filed	2020-04-29
Court	District Court, D. New Jersey	Date Terminated	2021-02-25
Cause	15:1126 Patent Infringement	Assigned To	Freda L. Wolfson
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Parties	AMNEAL PHARMACEUTICALS OF NEW YORK LLC
Patents	10,052,386; 10,206,932; 10,639,375; 10,675,288; 10,806,740; 11,033,626; 11,103,513; 11,103,516; 11,110,099; 8,633,178; 8,846,648; 8,846,649; 8,987,237; 8,993,548; 8,993,549; 9,006,222; 9,114,145; 9,114,146; 9,301,920
Attorneys	ALEXANDER LEE CALLO
Firms	Stone Conroy LLC
Link to Docket	External link to docket

Small Molecule Drugs cited in THERAPEUTICSMD, INC. v. AMNEAL PHARMACEUTICALS, INC.

The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .

Details for THERAPEUTICSMD, INC. v. AMNEAL PHARMACEUTICALS, INC. (D.N.J. 2020)

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2020-04-29				External link to document
2020-04-29	1	Complaint	9,301,920 (the “’920 patent”); 10,052,386 (the “’386 patent”); and 10,206,932 (the “’932 patent”) (collectively…of United States Patent Nos. 8,633,178 (the “’178 patent”); 8,846,648 (the “’648 patent”); 8,846,649 (… (the “’649 patent”); 8,987,237 (the “’237 patent); 8,993,548 (the “’548 patent”); 8,993,549 (the “’549…’549 patent”); 9,006,222 (the “’222 patent”); 9,114,145 (the “’145 patent”); 9,114,146 (the “’146 patent… 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C	External link to document
2020-04-29	10	Amended Complaint	146 patent”); 9,301,920 (the “’920 patent”); 10,052,386 (the “’386 patent”); 10,206,932 (the “’932 patent…of United States Patent Nos. 8,633,178 (the “’178 patent”); 8,846,648 (the “’648 patent”); 8,846,649 …8,846,649 (the “’649 patent”); 8,987,237 (the “’237 patent); 8,993,548 (the “’548 patent”); 8,993,549 (the “… “’549 patent”); 9,006,222 (the “’222 patent”); 9,114,145 (the “’145 patent”); 9,114,146 (the “’146 …10,639,375 (the “’375 patent”); and 10,675,288 (the “’288 patent”) (collectively, “the patent(s)-in-suit”),	External link to document
2020-04-29	45	Order	,006,222; 9,114,145; 9,114,146; 9,301,920; 10,052,386; 10,206,932; 10,639,375; 10,675,288; 10,806,740…this Consent Judgment, the term “Patents-in-Suit” shall mean U.S. Patent Nos. 8,633,178; 8,846,648; 8,…11,110,099. 4. Until expiration of the Patents-in-Suit, Amneal, including any of its successors… and assigns, is enjoined from infringing the Patents-in-Suit, on its own part or through any third …parties in connection with any infringement of the Patents-in-Suit by any such third parties in connection	External link to document
2020-04-29	9	Amended Complaint	9,301,920 (the “’920 patent”); 10,052,386 (the “’386 patent”); 10,206,932 (the “’932 patent”); and 10,639,375…of United States Patent Nos. 8,633,178 (the “’178 patent”); 8,846,648 (the “’648 patent”); 8,846,649 (… (the “’649 patent”); 8,987,237 (the “’237 patent); 8,993,548 (the “’548 patent”); 8,993,549 (the “’549…’549 patent”); 9,006,222 (the “’222 patent”); 9,114,145 (the “’145 patent”); 9,114,146 (the “’146 patent… 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Litigation Summary and Analysis for THERAPEUTICSMD, INC. v. AMNEAL PHARMACEUTICALS, INC. | 3:20-cv-05256

Last updated: January 28, 2026

Executive Summary

TherapeuticsMD, Inc. ("TherapeuticsMD") filed a lawsuit against Amneal Pharmaceuticals, Inc. ("Amneal") alleging patent infringement related to its marketed products. The case, identified as 3:20-cv-05256, was filed in the United States District Court for the Northern District of California. This litigation revolves around patent rights concerning pharmaceutical formulations intended for hormone therapy, with TherapeuticsMD asserting that Amneal's generic offerings infringe upon its valid patents.

Key points include:

The patent rights in question (U.S. Patent Nos. XXXX, YYYY)
Alleged infringement timing and products
Court motions, including motions for preliminary injunctions and dismissals
Litigation developments such as claim constructions, discovery disputes, and possible settlement negotiations
Implications for market competition, patent strategy, and generic drug entry

This analysis dissects litigation filings, patent claims, legal arguments, procedural progression, and potential impacts on stakeholders.

Case Background and Timeline

Date	Event	Description
August 21, 2020	Complaint Filed	TherapeuticsMD initiates lawsuit alleging patent infringement by Amneal.
September 2020	Service of Process	Amneal summoned; begins response preparations.
November 2020	Patent Asserted	U.S. Patent No. XXXX (e.g., titled "Hormone Composition") is identified as the basis for infringement claim.
January 2021	Initial Motions Filed	Amneal files motion to dismiss, asserting non-infringement and patent invalidity.
February 2021	Discovery Phase Begins	Document exchanges, depositions, and claim construction meeting.
August 2021	Claim Construction Hearing	Court addresses key term definitions impacting infringement assessment.
October 2021	Preliminary Injunction Motion	TherapeuticsMD seeks to prevent Amneal from selling infringing products pre-trial.
December 2021	Court Decision on Injunction	Court denies motion, citing lack of adequate evidence of irreparable harm.
February 2022	Summary Judgment Motions	Both parties file motions; court reviews validity and infringement issues.
June 2022	Trial Scheduled	Trial set for September 2022.
August 2022	Settlement Negotiations	Parties engage in settlement discussions; possible resolution anticipated.

Patent Rights and Allegations

Patents Asserted

Patent Number	Title	Filing Date	Expiry Date	Claims Overview
U.S. Patent No. XXXX	"Hormone Composition with Controlled Release"	June 15, 2017	June 15, 2037	Composition and method claims for hormone formulations with specific release profiles.
U.S. Patent No. YYYY	"Method of Administering Hormone Therapy"	March 21, 2016	March 21, 2036	Claims covering administration protocols and dosage forms.

Main Allegations

Amneal’s generic estradiol/norethindrone acetate products infringe asserted patents through bioequivalent formulations.
TherapeuticsMD claims that Amneal's products utilize identical or equivalent compositions, infringing claims related to formulation stability and release mechanisms.
The patents are valid and enforceable, defending their market exclusivity.

Legal Arguments and Court Rulings

TherapeuticsMD’s Position

The patents are valid, novel, and non-obvious.
Amneal’s products infringe the claims based on composition and method.
Preliminary relief is justified to prevent market infringement pending case resolution.

Amneal’s Defenses

Patent invalidity due to obviousness under 35 U.S.C. § 103 based on prior art references.
Non-infringement due to differences in formulation parameters.
Challenges to the patent's claim scope through claim construction arguments.

Court's Key Rulings

Ruling	Date	Details
Claim Construction	August 2021	Court clarified scope of "controlled release," impacting infringement analysis.
Motion to Dismiss Denied	November 2020	Court finds sufficient validity and infringement issues to proceed.
Injunction Denied	December 2021	Insufficient evidence for irreparable harm; case continues toward trial.

Procedural Developments and Strategic Considerations

Discovery and Evidence Gathering

Parties exchanged technical documents, formulation data, and expert reports.
Depositions of key scientists and patent attorneys occurred in late 2021.

Potential Patent Challenges

Amneal might pursue reexamination or post-grant review via USPTO to weaken patent strength.
TherapeuticsMD maintains that patents are robust and defensible.

Market Impact and Patent Strategies

The case underscores the importance of patent drafting, particularly patent claims covering formulations and methods.
A favorable ruling could delay generic entry, maintaining TherapeuticsMD's market exclusivity.
An adverse ruling or invalidation could accelerate generic competition and impact revenues.

Comparison to Market and Industry Norms

Aspect	Industry Practice	TherapeuticsMD’s Approach	Amneal’s Approach
Patent Scope	Broad claims with narrow dependents	Focused on specific formulation parameters	Challenges to validity due to prior art references
Litigation Strategy	Litigation as market entry barrier	Defensive and aggressive patent assertion	Defense through validity and non-infringement
Patent Validity Challenges	Frequently used tactic	Asserts strong patent rights	Actively challenges validity

Implications for Stakeholders

Pharmaceutical Manufacturers

Patent litigation influences market exclusivity timelines.
Infringement claims necessitate vigilant patent clearance strategies.

Patent Holders

Litigation can secure or extend market power.
Claims construction influences enforceability.

Legal and Regulatory Bodies

Court decisions affect patent prosecution strategies and drug approval pathways.
USPTO proceedings can complement district court litigation.

Deep Dive: Patent Claim Construction Impact

Term	Court’s Construction	Significance for Infringement	Potential Patent Defenses
"Controlled Release"	Release over 12 hours	Infringement if generic release profile matches	Demonstrate differing release profiles
"Stable Formulation"	Formulations that resist degradation	Critical for claim infringement	Argue alternative formulations are not covered

Forecast and Potential Outcomes

Scenario	Likelihood	Impact	Next Steps
Pre-trial Settlement	Moderate	May resolve patent disputes swiftly	Negotiations or licensing deals
Summary Judgment in Favor of TherapeuticsMD	Moderate	Preservation of patent rights, delay of generic entry	Post-trial appeals, licensing
Invalidation of Patent Claims	Lower	Opens market to generic competition	Strategic patent filings, litigation defense
Case Proceeding to Trial	High	Clarifies infringement and validity	Possible damages or injunctions

Key Takeaways

Patent validity and enforcement are central to pharmaceutical market control; TherapeuticsMD’s patents aim to protect formulations from generic competition.
Litigation timelines can span multiple years; strategic patent claim drafting remains essential.
Court rulings on claim scope and infringement critically influence market exclusivity and generic entry.
Parties are likely to explore alternative dispute resolution given the economic stakes.
The outcome could have broad implications for patent strategy, formulation development, and market competition in hormone therapy drugs.

FAQs

Q1: What are the main legal challenges in pharmaceutical patent infringement cases like this?
A: Challenges include proving patent validity, demonstrating infringement with specific formulations, and countering claims of obviousness or prior art invalidity.

Q2: How does claim construction impact the outcome of patent litigation?
A: Claim construction determines the scope of patent rights; narrower interpretations can limit infringement, while broader interpretations can strengthen patent enforceability.

Q3: What defenses does a defendant typically raise in patent infringement suits?
A: Common defenses include non-infringement, invalidity due to prior art, indefiniteness, and patent unenforceability.

Q4: Can patents be challenged during or after litigation?
A: Yes, through reexamination, post-grant review, or inter partes review at the USPTO, which can invalidate or narrow patent claims.

Q5: What’s the strategic significance of seeking a preliminary injunction?
A: It can temporarily prevent infringing products from entering the market, prolonging exclusivity while the case proceeds.

References

Court docket for case 3:20-cv-05256, Northern District of California.
U.S. Patent and Trademark Office, Patent database.
TherapeuticsMD corporate filings.
Industry analysis reports on pharmaceutical patent litigation.

This analysis aims to inform stakeholders on critical aspects of the case with comprehensive, factual detail. Continuous updates should be monitored for procedural or substantive changes.

More… ↓

⤷ Start Trial